Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Panobinostat in Combination With Rituximab For Relapsed/Refractory Diffuse Large B Cell Lymphoma

NCT01282476 is registered in ClinicalTrials.gov with Massachusetts General Hospital as lead sponsor.

NCT NCT01282476
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01282476 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Panobinostat in Combination With Rituximab For Relapsed/Refractory Diffuse Large B Cell Lymphoma
Lead sponsor
Massachusetts General Hospital
Phase
Phase 2
Overall status
Terminated
Start date
June 30, 2011
Completion date
August 31, 2014
Enrollment
18 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b cell lymphoma